氯雷他定血药浓度的HPLC荧光检测法及生物等效性研究

目的建立高效液相色谱法荧光检测血浆中氯雷他定(loratadine)含量的方法,以评价氯雷他定的相对生物利用度。方法色谱柱为Alltech C₁₈,4.6 mm×150 mm;流动相为乙腈-水-冰醋酸-三乙胺(90∶100∶6∶0.15);流速为1 mL·min^-1;荧光检测器测定波长,E_x＝274 nm,E_m＝450 nm。结果HPLC测定线性范围为0.2～30 μg·L^-1,最低定量限0.2 μg·L^-1,方法回收率为96％～98％。人体生物利用度结果表明,实验片、胶囊与对照片间的AUC,t_max,C_max和t_1/2β均无显著性差异(P>0.05),两者的相对生物利用度分别为107%±17%和100%±14%。AUC和C_max经可信区间法检验生物等效。结论3种制剂生物等效。

Determination of loratadine in human plasma by HPLC with fluorescence detector and study on its bioavailability

AIM: To establish an HPLC-fluorescence method for determination of loratadine in human plasma and evaluate its relative bioavailability. METHODS: An Alltech-C18 column and a mobile phase of acetonitrile-water-glacial acetic acid-triethylamine (90:100:6:0.15) were used. The fluorescence detector was set at Ex 274 nm, Em 450 nm. The flow rate was 1 mL.min-1. RESULTS: The calibration curve was linear over a concentration range of 0.2-30 micrograms.L-1. The limit of quantification was 0.2 microgram.L-1. The average method recoveries varied from 96% to 98%. The results showed AUC, Tmax, Cmax and T1/2 beta between the testing tablets, testing capsules and reference tablets had no significant difference (P > 0.05). Relative bioavailabilities were 107% +/- 17% and 100% +/- 14% respectively. CONCLUSION: The three formulations were bioequivalent.